查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1924661

Enzalutamide药品市场依品牌类型、适应症、剂型、剂量强度、最终用户及通路划分－2026-2032年全球预测

Enzalutamide Drugs Market by Brand Type, Indication, Formulation, Dosage Strength, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，Enzalutamide药品市场价值将达到 69.7 亿美元，到 2026 年将成长至 75 亿美元，到 2032 年将达到 125.1 亿美元，复合年增长率为 8.71%。

关键市场统计数据
基准年 2025 69.7亿美元
预计年份：2026年 75亿美元
预测年份 2032 125.1亿美元
复合年增长率 (%) 8.71%

Enzalutamide的策略实施定位使其能够适应不断发展的临床实践、支付方优先事项和相互竞争的生命週期管理趋势。

Enzalutamide已成为现代摄护腺癌治疗的核心选择之一，影响着多种疾病阶段的治疗路径。近期临床实践的改变、监管核准的批准以及竞争对手的涌入，使得临床讨论的范围从晚期转移性疾病扩展到更早期的治疗阶段和辅助性治疗治疗领域。因此，价值链上的相关人员——包括临床医生、支付方、生产商和专科药房——必须整合不断更新的证据和实际营运情况，以确定其市场定位、获取途径和供应策略。本导言概述了恩札卢胺的核心药理特性、一般临床作用以及界定相关人员优先事项的策略要务，从而为更广泛的背景分析奠定基础。

不断发展的临床证据、监管细则和商业性创新将如何重塑Enzalutamide的使用和竞争动态

由于临床证据的不断更新、监管措施的调整以及商业性创新，Enzalutamide市场格局发生了显着变化。临床试验和真实世界研究正在将治疗讨论扩展到疾病早期阶段和复杂的患者亚群，迫使临床医生重新考虑治疗顺序和联合用药策略。同时，监管机构正在完善药品附加檔和上市后核准要求，这影响处方模式以及生产商为维持市场接受度而必须提供的证据。这些临床和监管趋势正在推动商业模式的变革，这些变革强调患者援助计划、数位化药物管理工具和整合式护理路径，以改善治疗效果并减少就医障碍。

评估近期关税调整对癌症药物筹资策略、供应链韧性和分销模式的营运影响。

关税措施的加强和贸易政策的更新为关键肿瘤治疗药物的生产商、经销商和医疗服务提供者带来了新的考虑。关税分类的变化、活性药物成分进口关税的调整以及对跨境供应链日益严格的审查，都在影响采购决策和服务成本分析。这些政策变化促使各机构重新评估其製造地、供应商多元化策略和库存管理政策，以降低贸易波动带来的风险，同时确保依赖持续治疗的患者的医疗服务不受影响。

将适应症细微差别、品牌类型、终端用户行为和分销管道差异与策略性市场行动联繫起来的综合細項分析

深入了解Enzalutamide市场区隔对于理解市场格局、制定针对患者族群、通路合作伙伴和产品组合的商业性和临床策略至关重要。根据适应症，转移性去势抗性前列腺癌、转移性荷尔蒙敏感性前列腺癌和非转移性去势抗性前列腺癌的价值提案必须有所区别。这是因为每种适应症都有其独特的临床终点、治疗顺序考量和支付方评估标准。根据品牌类型，核准的学名药、品牌製剂和完全非品牌学名药之间的策略选择差异显着，这会影响合约签订、定价策略和患者支援投入。根据最终用户，医院、零售药局和专科癌症中心的供应和服务模式各不相同。医院又分为私立和公立，专科癌症中心又分为大学附属肿瘤中心和私立肿瘤中心。每种模式都有其自身的采购方式、临床试验合作和处理集管理。

区域监管差异、支付方生态系统和分销基础设施如何影响全球市场的准入路径

区域趋势在塑造药物进入途径、监管互动和商业策略方面发挥着至关重要的作用，美洲、欧洲、中东和非洲以及亚太地区呈现出鲜明的特征。在美洲，市场进入往往由私人支付方和公共计画共同推动，成熟的肿瘤网络和肿瘤专科药房在分销和病患支援方面发挥核心作用。支付者的谈判和价值评估资料通常决定药物是否被列入医保目录，而临床指南的采纳和学术机构的影响可以加速某些适应症的药物推广。相较之下，欧洲、中东和非洲拥有多元化的法规结构和报销环境，既有集中式评估机制，也有国家层级的评估机制，导致该地区药物进入时间和价格压力各不相同。

竞争动态和伙伴关係模式凸显了创新者、授权学名药和服务供应商如何塑造治疗方法差异化。

Enzalutamide领域的竞争格局呈现出多元化的特点，既有成熟的创新药企，也有获得授权的非专利参与企业、专科药商和合约服务供应商，共同构成了一个日益复杂的多层次竞争环境。药物研发公司致力于透过核准后临床试验来保护药物的生命週期价值，拓展适应症至疾病进展的早期阶段，并提供差异化服务，例如药物援助计划和综合患者支持。核准的非专利策略旨在平衡消费者对低成本替代品的需求与品牌药通路关係，而完全无品牌非专利则带来了传统的价格竞争和分销优化压力。

在不断变化的肿瘤学环境中，采取切实可行的战术性步骤和策略重点，以确保临床定位、供应连续性和与支付方的协调一致。

产业领导者应迅速调整其临床、商业和营运策略，以适应不断变化的治疗和政策环境。首先，他们应阐明自身的比较优势，优先进行符合支付方证据要求的研究，关注对临床医生和医疗系统至关重要的疗效指标，并支持药品目录和指南的采纳。其次，他们应透过供应商多元化、评估近岸外包方案以及加强库存分析来增强分销管道的韧性，从而减轻贸易政策变化对营运的影响。第三，他们应发展差异化的病人和医护人员支持模式，以提高病人的用药依从性，减少行政管理的摩擦，并向相关人员展现实际价值。

本分析所依据的调查方法严谨，结合了专家访谈、监管和临床文献综合以及交叉检验三角测量，从而提供策略性见解。

本分析所依据的研究结合了第一手和第二手研究方法，以确保对临床、商业性和营运动态有全面且平衡的理解。第一手研究包括对临床意见领袖、处方集、医院药房主任和分销主管进行结构化访谈，以收集关于临床应用、准入挑战和运营实践的第一手观点。第二手研究涵盖监管文件、同行评审文献、临床试验註册库和公共资讯来源，检验了标籤趋势、指南更新和贸易政策变化。透过对这些资讯检验，确保策略推理既有实证证据支持，又有实务经验支持。

整合策略意义，确保永续获取：强调基于证据的差异化、供应链韧性和相关人员的综合协作

累积分析凸显了当前市场环境的复杂性和动态性。临床进展不断拓展治疗可能性，而监管、竞争和贸易等因素也带来了执行上的挑战。关键主题包括：需要基于实证医学进行差异化；在贸易政策不断变化的情况下，建立具有韧性和多元化的供应链至关重要；以及针对不同终端使用者和分销管道製定客製化商业化策略的核心意义。未来，成功将越来越依赖一种能够整合临床开发、支付方证据、区域监管策略以及营运准备情况的策略，从而确保患者能够持续获得治疗。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章Enzalutamide药物市场（依品牌类型划分）

  • 品牌产品
  • 学名药

第九章Enzalutamide药物市场（依适应症划分）

  • 转移性去势去势抗性前列腺癌
  • 转移性荷尔蒙敏感性前列腺癌
  • 非转移性去势抗性前列腺癌

第十章Enzalutamide药物市场按剂型划分

  • 胶囊
  • 液体
  • 药片

第十一章Enzalutamide药物市场（以剂量强度划分）

  • 20毫克
  • 40毫克

第十二章Enzalutamide药物市场：依最终用户划分

  • 医院
    • 私立医院
    • 公立医院
  • 零售药房
  • 专科癌症中心

第十三章Enzalutamide药物市场（依通路划分）

  • 离线
  • 在线的

第十四章Enzalutamide药物市场（按地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章Enzalutamide药物市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 各国Enzalutamide药物市场概况

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章：美国Enzalutamide药物市场

第十八章：中国Enzalutamide药物市场

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Aarti Pharmalabs Limited
  • Aprazer Healthcare Private Limited
  • Astellas Pharma Inc.
  • BDR Pharmaceuticals International Private Limited
  • Cipla Limited
  • Dr. Reddy's Laboratories Limited
  • Glenmark Pharmaceuticals Limited
  • Hetero Healthcare Limited
  • Hunan Huateng Pharmaceutical Co., Ltd.
  • Intas Pharmaceuticals Limited
  • Laurus Labs Limited
  • MSN Laboratories Private Limited
  • Pfizer Inc.
  • RPG Life Sciences Limited
  • Shilpa Medicare Limited
  • Shivalik Rasayan Limited
  • Sun Pharmaceutical Industries Limited
  • Viatris Inc.
  • Zaklady Farmaceutyczne Polpharma SA
  • Zydus Lifesciences Limited
Product Code: MRR-7A380DA7C40A

The Enzalutamide Drugs Market was valued at USD 6.97 billion in 2025 and is projected to grow to USD 7.50 billion in 2026, with a CAGR of 8.71%, reaching USD 12.51 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 6.97 billion
Estimated Year [2026] USD 7.50 billion
Forecast Year [2032] USD 12.51 billion
CAGR (%) 8.71%

A strategic introduction that situates enzalutamide within evolving clinical practice, payer priorities, and competitive lifecycle management dynamics

Enzalutamide has become a central therapeutic option in contemporary prostate cancer care, influencing treatment pathways across multiple disease states. Recent shifts in clinical practice, regulatory approvals, and competitive entry have expanded the clinical conversation beyond late-stage metastatic disease to earlier treatment settings and adjuvant contexts. As a consequence, stakeholders across the value chain-clinicians, payers, manufacturers, and specialty pharmacies-must synthesize evolving evidence with operational realities to determine positioning, access, and supply strategies. This introduction frames the broader landscape by outlining core pharmacologic attributes, prevailing clinical roles, and the strategic imperatives that define stakeholder priorities.

Clinicians and oncology program leaders are balancing efficacy, tolerability, and sequencing considerations as new comparative evidence accumulates. Payers and health systems are recalibrating formularies and prior authorization protocols to incorporate real-world effectiveness and value-based considerations. Manufacturers and distribution partners are adapting their go-to-market approaches to emphasize patient support, adherence solutions, and differentiated service offerings that extend beyond the pill. Moreover, regulatory and intellectual property timelines remain pivotal in determining competitive dynamics, with authorized generics and branded alternatives shaping contracting and procurement strategies. Taken together, these factors create an environment where clear, actionable intelligence is essential for aligning commercial, clinical, and operational plans with the realities of modern oncology care.

How clinical evidence progression, regulatory refinement, and commercial innovation are reshaping enzalutamide use and competitive dynamics

The landscape for enzalutamide has experienced substantive transformative shifts driven by advances in clinical evidence, regulatory actions, and commercial innovation. Clinical trials and real-world studies have extended the therapeutic conversation into earlier disease settings and nuanced patient subgroups, prompting clinicians to reconsider sequencing and combination strategies. Concurrently, regulatory agencies have refined labeling and post-approval requirements, which has influenced prescribing patterns and the evidence manufacturers must generate to sustain utilization. These clinical and regulatory currents have catalyzed changes in commercial models, with an emphasis on patient support programs, digital adherence tools, and integrated care pathways to improve outcomes and reduce friction in access.

Parallel to these clinical and regulatory developments, competitive dynamics have evolved through increased interest in authorized generics and new entrants seeking to address cost and access barriers. Distribution and channel strategies have adapted accordingly: hospital systems and cancer centers are emphasizing integrated oncology pharmacy models while retail and online pharmacies innovate around fulfillment and patient convenience. Payers are increasingly deploying outcomes-based agreements and tailored utilization management to balance access with budgetary stewardship. The resulting environment is one of heightened complexity but also of opportunity, as organizations that align clinical evidence generation with differentiated access and distribution approaches will be better positioned to capture value amid the evolving therapeutic paradigm.

Assessing the operational ripple effects of recent tariff adjustments on sourcing strategies, supply chain resilience, and distribution models for oncology therapies

The introduction of enhanced tariff measures and trade policy updates in the United States has introduced new considerations for manufacturers, distributors, and healthcare providers involved with critical oncology therapies. Changes in tariff classifications, adjustments to import duties on active pharmaceutical ingredients, and tightened scrutiny of cross-border supply chains have influenced sourcing decisions and cost-to-serve analyses. These policy shifts have encouraged organizations to reevaluate their manufacturing footprints, supplier diversification strategies, and inventory management policies to reduce exposure to trade-related volatility while maintaining continuity of care for patients reliant on therapeutic consistency.

In response, many manufacturers have accelerated nearshoring initiatives and sought greater vertical integration of critical supply chain nodes. Contract manufacturers and ingredient suppliers are being assessed not only on traditional quality and cost metrics but also on resiliency under new trade regimes. Distribution partners have adapted contractual terms to reflect greater risk-sharing and to ensure transparent pass-through of tariff impacts where applicable. Health systems and oncology providers are adjusting procurement practices, increasing buffer stocks for critical therapies, and collaborating more closely with suppliers to avoid supply disruptions. Collectively, these measures reflect a broader strategic recalibration that prioritizes supply chain resilience and operational continuity in the face of evolving trade policy dynamics.

Comprehensive segmentation insights linking indication nuances, brand typologies, end user behaviors, and channel distinctions to strategic market actions

A granular understanding of segmentation is essential to navigating the enzalutamide landscape and tailoring commercial and clinical strategies across patient cohorts, channel partners, and product configurations. Based on indication, stakeholders must differentiate value propositions for metastatic castration-resistant prostate cancer, metastatic hormone-sensitive prostate cancer, and non-metastatic castration-resistant prostate cancer, since each indication carries distinct clinical endpoints, treatment sequencing considerations, and payer evaluation criteria. Based on brand type, strategic choices differ markedly between authorized generic offerings, branded formulations, and fully unbranded generics, affecting contracting, pricing strategies, and patient support investments. Based on end user, supply and service models vary across hospitals, retail pharmacies, and specialized cancer centers, with hospitals further divided into private and public settings and specialized cancer centers split between academic and private oncology centers, each presenting unique purchasing practices, clinical trial linkages, and formulary governance.

Based on distribution channel, stakeholders must design differentiated approaches for hospital pharmacies, online pharmacies, retail pharmacies, and wholesale distributors, with further nuance between general and oncology hospital pharmacies, manufacturer direct and third-party online models, chain versus independent retail formats, and national versus regional distributors. Based on formulation, market access and patient adherence strategies differ for capsules, solutions, and tablets, and packaging formats such as blister versus bottle packs for capsules or film coated versus uncoated tablets can influence dispensing preferences and patient experience. Finally, based on dosage strength, clinical usage patterns and packaging decisions diverge across twenty milligram and forty milligram strengths, with the forty milligram strength presenting additional considerations when offered in multi-dose versus single-dose packaging. Strategically integrating these segmentation lenses enables more precise targeting of clinical evidence generation, contracting, and distribution investments.

How regional regulatory diversity, payer ecosystems, and distribution infrastructures create differentiated pathways to access across global markets

Regional dynamics are instrumental in shaping access pathways, regulatory interactions, and commercial strategies, with distinct characteristics evident across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, market access tends to be driven by a mix of private payers and public programs, with established oncology networks and oncology-focused pharmacies playing a central role in distribution and patient support. Payer negotiations and value dossiers commonly determine formulary placement, while clinical guideline adoption and academic center influence can accelerate uptake in specific indications. In contrast, Europe, Middle East & Africa presents a heterogeneous mix of regulatory frameworks and reimbursement environments where centralized and country-level assessment mechanisms coexist, creating variable access timelines and diverse pricing pressures.

Asia-Pacific encompasses a wide spectrum of development and access realities, from highly regulated markets with strong pharmacovigilance systems to emerging markets where supply chain constraints and affordability considerations are more pronounced. Across these regions, regulatory expectations for local evidence generation, pricing transparency, and patient assistance programs vary, requiring manufacturers to develop region-specific strategies that balance global standards with local operational realities. Collaboration with local clinical leaders, tailored health economic submissions, and adaptive distribution models are recurrent themes that influence successful regional execution. Navigating these geographic distinctions demands both centralized strategic coherence and decentralized operational agility to respond to regulatory and payer idiosyncrasies.

Competitive dynamics and partnership models highlighting how innovators, authorized generics, and service providers are shaping therapeutic differentiation

Competitive activity in the enzalutamide space is characterized by a mix of established innovators, authorized generic entrants, specialized manufacturers, and contract services providers, each contributing to an increasingly layered competitive landscape. Innovator companies focus on protecting lifecycle value through post-approval trials, label expansions into earlier disease settings, and service-based differentiation such as adherence programs and integrated patient support. Authorized generic strategies are being deployed to balance demand for lower-cost alternatives while preserving branded channel relationships, and fully unbranded generics introduce traditional price competition and distribution optimization pressures.

Strategic alliances, licensing agreements, and manufacturing partnerships are common as firms seek to secure supply security, extend geographic reach, and accelerate commercialization timelines. Contract manufacturing organizations and specialized distributors play a growing role in enabling scale, improving cost structures, and supporting compliance with evolving quality and trade policies. At the same time, newer entrants and smaller specialty firms emphasize nimble commercialization tactics and targeted relationship building with cancer centers and payers. Across the competitive spectrum, differentiation increasingly hinges on value-added services-such as real-world evidence initiatives, digital adherence tools, and patient financial navigation-that complement the core therapeutic offering and influence uptake across diverse care settings.

Practical tactical moves and strategic priorities to secure clinical positioning, supply continuity, and payer alignment in a shifting oncology environment

Industry leaders should act decisively to align clinical, commercial, and operational strategies with the evolving therapeutic and policy environment. First, prioritize evidence generation that clarifies comparative positioning and addresses payer evidence requirements, focusing on outcomes that matter to clinicians and health systems to support formulary inclusion and guideline adoption. Second, invest in distribution resilience by diversifying supplier bases, evaluating nearshoring options, and enhancing inventory analytics to mitigate the operational impact of trade policy shifts. Third, develop differentiated patient and provider support models that improve adherence, reduce administrative friction, and demonstrate real-world value to stakeholders.

Additionally, adapt pricing and contracting approaches to reflect the competitive presence of authorized generics and unbranded alternatives by exploring value-based contracting and risk-sharing arrangements where appropriate. Strengthen regional strategies through tailored regulatory plans and local stakeholder engagement, ensuring that health economic evidence and real-world data address local payer concerns. Finally, prioritize partnerships with specialty pharmacies, academic centers, and clinical networks to accelerate voice-of-clinician feedback loops and to support targeted education initiatives. By integrating these priority actions, industry leaders can better manage uncertainty, protect clinical positioning, and drive sustainable access across complex market environments.

Methodological rigor combining primary expert interviews, regulatory and clinical literature synthesis, and cross-validated triangulation to inform strategic insights

The research underpinning this analysis synthesizes primary and secondary methodologies to ensure a robust, balanced understanding of clinical, commercial, and operational dynamics. Primary research included structured interviews with clinical opinion leaders, formulary decision-makers, hospital pharmacy directors, and distribution executives to capture on-the-ground perspectives about clinical use, access challenges, and operational practices. Secondary research encompassed regulatory documents, peer-reviewed literature, clinical trial registries, and public policy sources to validate trends in labeling, guideline updates, and trade policy changes. Triangulation of these inputs ensured that strategic inferences were grounded in both empirical evidence and practitioner insight.

Data integrity was maintained through cross-validation across multiple independent sources and by subjecting thematic findings to expert review. Segmentation analysis incorporated both clinical and commercial lenses to reflect the multifaceted nature of therapeutic adoption and channel behaviors, while regional analysis relied on local regulatory documentation and payer guidance to reflect jurisdictional differences. The methodology emphasized transparency in assumptions and a clear audit trail for insights to facilitate external validation and application by commercial and medical teams. Together, these methods provide a defensible basis for the strategic implications and recommendations presented.

Synthesis of strategic implications emphasizing evidence-driven differentiation, supply chain resilience, and integrated stakeholder collaboration for sustained access

The cumulative analysis highlights a market environment that is simultaneously dynamic and delicate, where clinical advances expand therapeutic potential while regulatory, competitive, and trade variables introduce material executional complexity. Key themes include the necessity of evidence-driven differentiation, the importance of resilient and diversified supply chains in the face of changing trade policy, and the centrality of tailored commercialization strategies across distinct end users and distribution channels. Success will increasingly rely on an integrated approach that aligns clinical development with payer evidence, regional regulatory strategies, and operational readiness to deliver consistent patient access.

Looking ahead, organizations that proactively invest in robust real-world evidence programs, cultivate flexible manufacturing and distribution capabilities, and build differentiated service models for providers and patients will be better positioned to navigate uncertainty. Collaborative engagement across the ecosystem-bringing clinicians, payers, distributors, and manufacturers into earlier and more structured dialogues-will accelerate problem-solving and reduce time-to-access for patients. Ultimately, strategic foresight combined with operational discipline will determine which stakeholders can sustain clinical relevance and commercial viability in a rapidly evolving therapeutic landscape.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Enzalutamide Drugs Market, by Brand Type

  • 8.1. Branded
  • 8.2. Generic

9. Enzalutamide Drugs Market, by Indication

  • 9.1. Metastatic Castration-Resistant Prostate Cancer
  • 9.2. Metastatic Hormone-Sensitive Prostate Cancer
  • 9.3. Non-Metastatic Castration-Resistant Prostate Cancer

10. Enzalutamide Drugs Market, by Formulation

  • 10.1. Capsules
  • 10.2. Solution
  • 10.3. Tablet

11. Enzalutamide Drugs Market, by Dosage Strength

  • 11.1. 20 Milligram
  • 11.2. 40 Milligram

12. Enzalutamide Drugs Market, by End User

  • 12.1. Hospitals
    • 12.1.1. Private Hospitals
    • 12.1.2. Public Hospitals
  • 12.2. Retail Pharmacies
  • 12.3. Specialized Cancer Centers

13. Enzalutamide Drugs Market, by Distribution Channel

  • 13.1. Offline
  • 13.2. Online

14. Enzalutamide Drugs Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Enzalutamide Drugs Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Enzalutamide Drugs Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Enzalutamide Drugs Market

18. China Enzalutamide Drugs Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Aarti Pharmalabs Limited
  • 19.6. Aprazer Healthcare Private Limited
  • 19.7. Astellas Pharma Inc.
  • 19.8. BDR Pharmaceuticals International Private Limited
  • 19.9. Cipla Limited
  • 19.10. Dr. Reddy's Laboratories Limited
  • 19.11. Glenmark Pharmaceuticals Limited
  • 19.12. Hetero Healthcare Limited
  • 19.13. Hunan Huateng Pharmaceutical Co., Ltd.
  • 19.14. Intas Pharmaceuticals Limited
  • 19.15. Laurus Labs Limited
  • 19.16. MSN Laboratories Private Limited
  • 19.17. Pfizer Inc.
  • 19.18. RPG Life Sciences Limited
  • 19.19. Shilpa Medicare Limited
  • 19.20. Shivalik Rasayan Limited
  • 19.21. Sun Pharmaceutical Industries Limited
  • 19.22. Viatris Inc.
  • 19.23. Zaklady Farmaceutyczne Polpharma S.A.
  • 19.24. Zydus Lifesciences Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ENZALUTAMIDE DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ENZALUTAMIDE DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY BRAND TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES ENZALUTAMIDE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA ENZALUTAMIDE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY BRANDED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY BRANDED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY BRANDED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY GENERIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY GENERIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY GENERIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY METASTATIC CASTRATION-RESISTANT PROSTATE CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY METASTATIC CASTRATION-RESISTANT PROSTATE CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY METASTATIC CASTRATION-RESISTANT PROSTATE CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY METASTATIC HORMONE-SENSITIVE PROSTATE CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY METASTATIC HORMONE-SENSITIVE PROSTATE CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY METASTATIC HORMONE-SENSITIVE PROSTATE CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY SOLUTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY SOLUTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY SOLUTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY TABLET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY TABLET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY 20 MILLIGRAM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY 20 MILLIGRAM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY 20 MILLIGRAM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY 40 MILLIGRAM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY 40 MILLIGRAM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY 40 MILLIGRAM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY SPECIALIZED CANCER CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY SPECIALIZED CANCER CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY SPECIALIZED CANCER CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. AMERICAS ENZALUTAMIDE DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 62. AMERICAS ENZALUTAMIDE DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 63. AMERICAS ENZALUTAMIDE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 64. AMERICAS ENZALUTAMIDE DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 65. AMERICAS ENZALUTAMIDE DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 66. AMERICAS ENZALUTAMIDE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS ENZALUTAMIDE DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS ENZALUTAMIDE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 69. NORTH AMERICA ENZALUTAMIDE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. NORTH AMERICA ENZALUTAMIDE DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 71. NORTH AMERICA ENZALUTAMIDE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 72. NORTH AMERICA ENZALUTAMIDE DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA ENZALUTAMIDE DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 74. NORTH AMERICA ENZALUTAMIDE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA ENZALUTAMIDE DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA ENZALUTAMIDE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 77. LATIN AMERICA ENZALUTAMIDE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. LATIN AMERICA ENZALUTAMIDE DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. LATIN AMERICA ENZALUTAMIDE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA ENZALUTAMIDE DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 81. LATIN AMERICA ENZALUTAMIDE DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 82. LATIN AMERICA ENZALUTAMIDE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA ENZALUTAMIDE DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA ENZALUTAMIDE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA ENZALUTAMIDE DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA ENZALUTAMIDE DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA ENZALUTAMIDE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA ENZALUTAMIDE DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE, MIDDLE EAST & AFRICA ENZALUTAMIDE DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE, MIDDLE EAST & AFRICA ENZALUTAMIDE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE, MIDDLE EAST & AFRICA ENZALUTAMIDE DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA ENZALUTAMIDE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE ENZALUTAMIDE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE ENZALUTAMIDE DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE ENZALUTAMIDE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE ENZALUTAMIDE DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE ENZALUTAMIDE DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE ENZALUTAMIDE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE ENZALUTAMIDE DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE ENZALUTAMIDE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 101. MIDDLE EAST ENZALUTAMIDE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. MIDDLE EAST ENZALUTAMIDE DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. MIDDLE EAST ENZALUTAMIDE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 104. MIDDLE EAST ENZALUTAMIDE DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 105. MIDDLE EAST ENZALUTAMIDE DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 106. MIDDLE EAST ENZALUTAMIDE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST ENZALUTAMIDE DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST ENZALUTAMIDE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 109. AFRICA ENZALUTAMIDE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. AFRICA ENZALUTAMIDE DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. AFRICA ENZALUTAMIDE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 112. AFRICA ENZALUTAMIDE DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 113. AFRICA ENZALUTAMIDE DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 114. AFRICA ENZALUTAMIDE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. AFRICA ENZALUTAMIDE DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 116. AFRICA ENZALUTAMIDE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC ENZALUTAMIDE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC ENZALUTAMIDE DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC ENZALUTAMIDE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC ENZALUTAMIDE DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC ENZALUTAMIDE DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC ENZALUTAMIDE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC ENZALUTAMIDE DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC ENZALUTAMIDE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. ASEAN ENZALUTAMIDE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. ASEAN ENZALUTAMIDE DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. ASEAN ENZALUTAMIDE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 129. ASEAN ENZALUTAMIDE DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 130. ASEAN ENZALUTAMIDE DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 131. ASEAN ENZALUTAMIDE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN ENZALUTAMIDE DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 133. ASEAN ENZALUTAMIDE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 134. GCC ENZALUTAMIDE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. GCC ENZALUTAMIDE DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. GCC ENZALUTAMIDE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 137. GCC ENZALUTAMIDE DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 138. GCC ENZALUTAMIDE DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 139. GCC ENZALUTAMIDE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. GCC ENZALUTAMIDE DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 141. GCC ENZALUTAMIDE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPEAN UNION ENZALUTAMIDE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPEAN UNION ENZALUTAMIDE DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPEAN UNION ENZALUTAMIDE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPEAN UNION ENZALUTAMIDE DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPEAN UNION ENZALUTAMIDE DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPEAN UNION ENZALUTAMIDE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPEAN UNION ENZALUTAMIDE DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPEAN UNION ENZALUTAMIDE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 150. BRICS ENZALUTAMIDE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. BRICS ENZALUTAMIDE DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. BRICS ENZALUTAMIDE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 153. BRICS ENZALUTAMIDE DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 154. BRICS ENZALUTAMIDE DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 155. BRICS ENZALUTAMIDE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. BRICS ENZALUTAMIDE DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 157. BRICS ENZALUTAMIDE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 158. G7 ENZALUTAMIDE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. G7 ENZALUTAMIDE DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. G7 ENZALUTAMIDE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 161. G7 ENZALUTAMIDE DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 162. G7 ENZALUTAMIDE DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 163. G7 ENZALUTAMIDE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 164. G7 ENZALUTAMIDE DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 165. G7 ENZALUTAMIDE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 166. NATO ENZALUTAMIDE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 167. NATO ENZALUTAMIDE DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. NATO ENZALUTAMIDE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 169. NATO ENZALUTAMIDE DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 170. NATO ENZALUTAMIDE DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 171. NATO ENZALUTAMIDE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. NATO ENZALUTAMIDE DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 173. NATO ENZALUTAMIDE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL ENZALUTAMIDE DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. UNITED STATES ENZALUTAMIDE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 176. UNITED STATES ENZALUTAMIDE DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. UNITED STATES ENZALUTAMIDE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 178. UNITED STATES ENZALUTAMIDE DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 179. UNITED STATES ENZALUTAMIDE DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 180. UNITED STATES ENZALUTAMIDE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 181. UNITED STATES ENZALUTAMIDE DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 182. UNITED STATES ENZALUTAMIDE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 183. CHINA ENZALUTAMIDE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 184. CHINA ENZALUTAMIDE DRUGS MARKET SIZE, BY BRAND TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. CHINA ENZALUTAMIDE DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 186. CHINA ENZALUTAMIDE DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 187. CHINA ENZALUTAMIDE DRUGS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 188. CHINA ENZALUTAMIDE DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. CHINA ENZALUTAMIDE DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 190. CHINA ENZALUTAMIDE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)